Have you ever felt like finding the right clinical trial is as complex as online dating, but without the fun swiping? At pRxEngage, we are revolutionising how patients and pioneering research connect, making the process as intuitive and empowering as finding your perfect match! The current scene in clinical trials is often slow, incredibly expensive, and frankly, fails both sponsors and the very patients it aims to help. While over 80% of patients are eager to join trials, a mere 30% actually do. This massive disconnect means trials are frequently delayed, racking up costs of £420,000 to over £6 million per day, and vital new drugs are stuck in development. We are here to change that. pRxEngage goes beyond simply recruiting; we’re about deep, sustained engagement. We look past just medical suitability to address whether a trial truly fits into a person’s life, helping them overcome any doubts. By making patients active ‘consumers’ of the trial, opting in at each stage, we build an ever-deepening relationship. The outcome? Better retention, greater adherence, and faster trial success. Our platform makes finding a trial as simple as swiping right or left. Our AI-powered system guides patients with easy-to-understand, jargon-free information and tools based on behavioural science, like Self-Determination Theory, to help them assess their suitability. Then, it seamlessly connects them directly to trial sites. For sponsors and sites, we provide real-time data dashboards and predictive analytics to identify suitable participants and improve retention. Our AI even helps streamline trial setup by parsing documents and generating clear summaries for participants. pRxEngage is engineered to redefine the connection between high-potential patients and appropriate clinical trials, accelerating crucial enrolment timelines. We foster sustained participant engagement, moving beyond conventional recruitment metrics to cultivate a more committed and informed cohort from the outset. This results in a higher-calibre, more dedicated participant pool from the initial stages, directly contributing to improved trial success rates, enhanced participant retention, and greater adherence to study protocols. We are truly unique because we combine community partnerships, predictive engagement, and operational support. We work with patients, sites, sponsors, charities, and patient organisations, building trust and integrating feedback. Our predictive tools identify engaged participants, and our operational support offers workflow and triage tools for sites and sponsors to boost efficiency. We are an additive solution, meaning we work alongside existing sponsor tools, making adoption easy. We are proud to be developing groups of community partners and ambassadors. This includes fantastic organisations like PiCC Unite, The PBC Foundation, and Don’tBePatient, with several more in advanced development. These collaborations are crucial to our mission of broadening awareness and access to research opportunities, ensuring that value and information remain within these communities. Our success springs from our visionary leadership and proven execution. Our Founder and CEO, Keith Berelowitz, brings over two decades of experience, having brought 12 drugs to market and achieved top-enrolling site status in numerous multi-centre trials. Charlie Myrick, our CTO, is a founding CTO with a background in architecting global engineering solutions and building HIPAA-certified SaaS patient tracking systems. Ethan Graff-Radford, our Head of Product, has experience in product management at an A16Z-backed company and has implemented agile methodologies for health-tech solutions. Our board members, David Guthrie and Daniel Graff-Radford, bring decades of experience shaping health-tech, scaling companies, and providing strategic technological oversight. This combined expertise means pRxEngage represents the convergence of profound clinical trial operational knowledge with sophisticated technological execution. Our intellectual property strategy focuses on our registered trademark for the pRxEngage brand, which is crucial for establishing our identity as we turn clinical trial interest into action. Beyond branding, we rely significantly on trade secrets to protect our unique algorithms, data analytics methodologies, behavioural science integration, and operational workflows. These elements fundamentally change the focus from mere recruiting to long-term patient engagement, retention, and measurable return on investment. Want to learn more about how pRxEngage is changing the game for clinical trials? Check out our company one-pager (https://docsend.com/v/y95hx/swiperightonresearch) and read our recent blog (https://docsend.com/v/y95hx/makingpatientfirstmeansomethingbeyondconsent) post to see our thinking in action. #pRxEngaged #GetpRxEngaged #ClinicalTrials #PatientEngagement #HealthcareInnovation #MedTech #ClinicalResearch
Progeria Research Foundation
The Progeria Research Foundation (PRF) was established in 1999 by the parents of Sam Berns, a child diagnosed with Progeria at the age of 2. Progeria is an ultra-rare fatal genetic condition that results in accelerated aging in children. PRF is the only non-profit organization solely dedicated to finding treatments and the cure for Progeria. Due to the ultra-rare nature of the disease, no for-profit institution will work to find a cure for this fatal disease so PRF has taken on the role of Drug Developer. In 2020 the first treatment for Progeria (lonafarnib) was FDA approved, followed by approvals in 2022 in the EU and 2024 in Japan. PRF now has a pipeline of investigative therapies that includes small molecules as well as RNA and Gene therapies.
Pathway to Cures/NBDF
Pathway to Cures (P2C) is the National Bleeding Disorders Foundation’s (NBDF) venture philanthropy fund created specifically to accelerate the development of cures and therapies across all inheritable blood and bleeding disorders. P2C makes investments in innovative therapies, and technologies, leveraging the deep resources and scientific community relationships of NBDF. NBDF provides services that allow developers to engage with and obtain insights from community members with an inheritable bleeding disorder.
Ontario Brain Institute
The Ontario Brain Institute (OBI) is a provincially funded, not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy. OBI’s collaborative team science approach promotes brain research, commercialization, and care by connecting researchers, clinicians, industry, patients, and their advocates to improve the lives of those living with brain disorders. For more information, visit braininstitute.ca
Ohio Life Sciences Association
Ohio Life Sciences (OLS) represents almost 4,900 individual business establishments statewide, championing the growth and innovation of Ohio’s life sciences industry to drive economic advancement and patient well-being.
Life Science Oklahoma
Life Science Oklahoma (LSOK) supports, advances, and promotes the growth and expansion of Oklahoma’s Life Science Industry. We facilitate a collaborative and supportive ecosystem that connects and assists industry stakeholders to advance innovation, economic development, and health outcomes in Oklahoma. LSOK unites stakeholders to create a robust environment for industry growth and to enhance the competitiveness and sustainability of Oklahoma’s life science sector on a national and global scale.
INSTITUT CURIE
The Institut Curie, France’s leading cancer center, brings together a research center of international renown and a state-of-the-art hospital complex that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, the Institut Curie brings together nearly 4,000 researchers, physicians, and healthcare professionals across three sites (Paris, Saint-Cloud, and Orsay) around its three core missions: care, research, and education. As a foundation recognized as being of public interest and authorized to receive donations and bequests, the Institut Curie is able, thanks to the support of its donors, to accelerate discoveries and thereby improve treatments and patients’ quality of life. | The Curie Institute is France’s leading center for cancer research and treatment. Founded in 1921 by Marie Curie, it brings together a world-renowned research center and a state-of-the-art hospital group that treats all types of cancer, including the rarest forms. Spread across three sites (Paris, Saint-Cloud, and Orsay) the Institute unites 3,800 professionals, including researchers, physicians, and healthcare staff, around its three core missions: research, care, and knowledge sharing.
IBEX Therapeutics SA
Ibex Therapeutics is Swiss biotech company developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis, debilitating conditions which very often occur as adverse effect of cancer chemo- and radiotherapy and affects the care journey and the quality of life of cancer patients. A de-risked and short path to registration and commercialization by 2028, as validated by the German health authority BfArM: the lead product (containing 2 water-based plant extracts) is produced in GMP conditions and has confirmed its efficacy and safety in a pilot study in cancer patients. Ibex Tx is raising CHF 3 million, of which 1.0+ million has already received soft commitments, with the largest part of the proceeds to fund a final pivotal clinical study, and some portfolio extensions (including a probiotic to synergize with the oral topical therapy, and a spray presentation to augment portability and convenience of use by ambulatory patients). Strong market fundamentals: sustained medical need (increasing incidence of cancer and use of mucositis-inducing therapies), and absence of reference treatment. Further, Ibex Tx will register the product in several geographies (EU, USA, Asia, BRICS), and sign licensing agreements to ensure efficient commercialization outside of Switzerland.
Drugs for Neglected Diseases initiative (DNDi)
The Drugs for Neglected Diseases initiative is an international not-for-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for diseases that disproportionately impact poor and marginalized people. | We discover, develop, and deliver new treatments for neglected patients around the world that are affordable and patient-friendly – and have already saved millions of lives. With offices on five continents, DNDi works to ensure the people most affected by neglected diseases are part of medical research and development, helping to set priorities, strengthen capacity, and deliver new treatments where they are needed most.